Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bayssas

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 1978
Preliminary results of a phase II trial of aclacinomycin in acute leukaemia and lymphosarcoma. An oncostatic anthracyclin that is rarely cardiotoxic and induces no alopeciaG Mathé, M Bayssas, J Gouveia, et al.
European Journal of Cancer (Oxford, England : 1990)|November 27, 2001
Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the ratG Cavaletti, G Tredici, M G Petruccioli, et al.
Journal of the National Cancer Institute|May 3, 1995
Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancerM J Piccart, M Gore, W Ten Bokkel Huinink, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1980
Vindesine: a new vinca alkaloidM Bayssas, J Gouveia, F de Vassal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1995
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of CancerB Chevallier, P Fumoleau, P Kerbrat, et al.
Journal of the National Cancer Institute|December 12, 1992
Phase I trial of Taxotere: five-day scheduleR Pazdur, R A Newman, B M Newman, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1978
Some new chemotherapeutic agents and combinations possibly available for new adjuvant therapies of minimal diseaseG Mathé, M Hayat, J L Misset, et al.
Anticancer Research|January 30, 2003
Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the ratG Cavaletti, M G Petruccioli, P Marmiroli, et al.
La Nouvelle Presse Medicale|March 31, 1979
[Cis-diammino-dichloro-platinum therapy of cancers; phase II therapeutic trial]M Hayat, M Bayssas, G Brulé, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials GroupU Bruntsch, B Heinrich, S B Kaye, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Cancer Chemotherapy and Pharmacology|January 1, 1978
Preliminary results of a phase II trial of aclacinomycin in acute leukaemia and lymphosarcoma. An oncostatic anthracyclin that is rarely cardiotoxic and induces no alopeciaG Mathé, M Bayssas, J Gouveia, et al.
European Journal of Cancer (Oxford, England : 1990)|November 27, 2001
Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the ratG Cavaletti, G Tredici, M G Petruccioli, et al.
Journal of the National Cancer Institute|May 3, 1995
Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancerM J Piccart, M Gore, W Ten Bokkel Huinink, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1980
Vindesine: a new vinca alkaloidM Bayssas, J Gouveia, F de Vassal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1995
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of CancerB Chevallier, P Fumoleau, P Kerbrat, et al.
Journal of the National Cancer Institute|December 12, 1992
Phase I trial of Taxotere: five-day scheduleR Pazdur, R A Newman, B M Newman, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1978
Some new chemotherapeutic agents and combinations possibly available for new adjuvant therapies of minimal diseaseG Mathé, M Hayat, J L Misset, et al.
Anticancer Research|January 30, 2003
Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the ratG Cavaletti, M G Petruccioli, P Marmiroli, et al.
La Nouvelle Presse Medicale|March 31, 1979
[Cis-diammino-dichloro-platinum therapy of cancers; phase II therapeutic trial]M Hayat, M Bayssas, G Brulé, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials GroupU Bruntsch, B Heinrich, S B Kaye, et al.
Pageof 3